Though Cantor’s William Tanner keeps SGYP’s capital needs and prospective dilution in mind, he is confident on Trulance’s uptake in the market.
H.C.
Investors snapped up Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares a day after the drug maker released its fourth-quarter results. Surprisingly, SGYP reported 4Q17 Trulance sales …
Ram Selvaraju slashes his target to $8 on slower Trulance ramp.
Three key biopharma trades from the highly-successful $78 billion Renaissance fund
Investors to get a better viewpoint of Trulance during today’s call, says analyst.
Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.
Hedge Fund Guru Mark Kingdon Isn’t Taking Any Risks with OTIC, SGYP, ATRS
Synergy Still Showcases Promising Commercial Trajectory in CIC Rodman & Renshaw analyst Ram Selvaraju still looks for momentum in Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) chronic idiopathic …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock is on the downward spiral today, to the harsh, discordant clang of 12% after the biotech firm released …